Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.96%
1,090.01
-10.56
-0.96%
—1,100.571,098.941,103.801,084.24——
SIXC
Communications
SIXC
Communications
SIXC
-0.30%
603.34
-1.81
-0.30%
—605.15605.15606.69602.76——
SIXE
Energy
SIXE
Energy
SIXE
+1.68%
1,215.24
+20.05
+1.68%
—1,195.191,204.711,221.691,204.71——
SIXI
Industrials
SIXI
Industrials
SIXI
-1.16%
1,719.76
-20.15
-1.16%
—1,739.911,734.501,734.501,710.67——
SIXM
Financials
SIXM
Financials
SIXM
+0.54%
642.01
+3.45
+0.54%
—638.56640.21645.32639.66——
SIXR
Staples
SIXR
Staples
SIXR
+1.12%
840.89
+9.32
+1.12%
—831.57840.48844.16834.54——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.62%
214.69
+1.33
+0.62%
—213.36213.36215.54212.77——
SIXT
Technology
SIXT
Technology
SIXT
-1.86%
3,173.97
-60.21
-1.86%
—3,234.183,171.863,195.363,145.46——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.20%
937.56
+1.91
+0.20%
—935.65937.31941.44933.16——
SIXV
Health care
SIXV
Health care
SIXV
+0.14%
1,451.33
+2.07
+0.14%
—1,449.261,454.771,462.651,448.97——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.67%
2,366.43
-16.02
-0.67%
—2,382.452,371.192,380.452,364.46——
IMM:ASX
Immutep Ltd
A$0.063
-11.27%
(-0.0080) 1D
Apr 28, 4:10:30 PM GMT+10  ·   AUD
All symbols
SymbolPriceChange% Change
Generating top insights for IMM...
Open
A$0.07
High
A$0.07
Low
A$0.06
Mkt. cap
94.17M
Avg. vol.
74.27M
Volume
47.54M
52-wk high
A$0.47
52-wk low
A$0.03
EPS
-A$0.06
Shares outstanding
1.47B
No. of employees
19
News stories
From sources across the web
Profile
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. Prima currently has three main products in its pipeline, all acquired with Immutep: Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer. IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline. IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
About Immutep Ltd
CEOMarc Voigt
Employees19
Founded2001
Headquarters-
SectorBiotechnology
Websiteimmutep.com
Last report
Jan 29, 2026
Fiscal Period
Q2 2026
Normalized EPS / Estimate
-/ -AUD
Revenue / Estimate
3.01M/ (- est.)AUD
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in AUD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in AUD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
948.05K
948.05K
3.01M
3.01M
Cost of goods sold
18.04M
18.04M
23.31M
23.31M
Cost of revenue
18.04M
18.04M
23.31M
23.31M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.21M
2.21M
2.71M
2.71M
Operating expense
2.21M
2.21M
2.71M
2.71M
Total operating expenses
20.25M
20.25M
26.03M
26.03M
Operating income
-19.30M
-19.30M
-23.01M
-23.01M
Other non operating income
195.00
195.00
-256.17K
-256.17K
EBT including unusual items
-19.53M
-19.53M
-22.43M
-22.43M
EBT excluding unusual items
-19.49M
-19.49M
-22.42M
-22.42M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-19.53M
-19.53M
-22.43M
-22.43M
Net profit margin
-2,059.84%
-2,059.84%
-744.36%
-744.36%
Earnings per share
-
-
-
-
Interest and investment income
1.08M
1.08M
798.85K
798.85K
Interest expense
-9.90K
-9.90K
-9.65K
-9.65K
Net interest expenses
1.07M
1.07M
789.20K
789.20K
Depreciation and amortization charges
-
-
-
-
EBITDA
-18.75M
-18.75M
-22.45M
-22.45M
Gain or loss from assets sale
593.00
593.00
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer